scholarly journals Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept

2019 ◽  
Vol 3 (7) ◽  
pp. 567-575 ◽  
Author(s):  
Justus G. Garweg ◽  
Jana Stefanickova ◽  
Carel Hoyng ◽  
Thomas Schmelter ◽  
Tobias Niesen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Aflibercept ◽  
Related Quality

scholarly journals PSS5 - VISION-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL AFLIBERCEPT: THE AQUA STUDY

2018 ◽  
Vol 21 ◽  
pp. S422-S423 ◽  
Author(s):  
J.G. Garweg ◽  
J. Stefanickova ◽  
C. Hoyng ◽  
T. Schmelter ◽  
T. Niesen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Aflibercept ◽  
Related Quality

scholarly journals The Effect of Ranibizumab Loading Treatment on Vision-Related Quality of Life in Diabetic Macular Edema

2021 ◽  
Vol 11 (3) ◽  
pp. 659-670
Author(s):  
Hatice Daldal ◽  
Mustafa Turkyilmaz ◽  
Melike Balikoglu Yilmaz ◽  
Ufuk Berberoglu
Keyword(s):  
Quality Of Life ◽  
Macular Edema ◽  
Intravitreal Injection ◽  
Diabetic Macular Edema ◽  
Macular Thickness ◽  
Loading Dose ◽  
The Third ◽  
Related Quality ◽  
Composite Scores

Aims: To investigate the changes in vision-related quality of life after a loading dose of three consecutive intravitreal ranibizumab (IVR) injections in patients with unilateral diabetic macular edema (DME). Materials and Methods: Fifty-two eyes of 52 patients who received IVR injections in only one eye with DME were included in our study. The following characteristics of the patients were recorded: gender, education status, marital status, work status, presence of chronic disease. The changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated at baseline (before treatment) and 1 month after the third intravitreal injection (after treatment). Patients were administered the Turkish form of the National Eye Institute 25-Item Visual Functions Questionnaire (NEI VFQ-25 TR). The quality of life scores assessed by the NEI VFQ-25 TR, the BCVA, intraocular pressure (IOP), and CMT measurements were compared at baseline (before treatment) and 1 month after the third intravitreal injection (after treatment). Results: We enrolled 52 patients (25 females, 27 males) in our study; mean age was 64.35 ± 9.26 years. After treatment, BCVA improved significantly (p = 0.001), and macular thickness decreased significantly (p < 0.001). All NEI VFQ-25 TR subscale scores were significantly higher after treatment (p < 0.05). However, no significant correlation was found between the change in BCVA and CMT and the change in NEI VFQ-25 TR subscale and composite scores. The increase in near activities scores was significantly higher in males (p = 0.020) and in the retired group (p = 0.022). There were no significant differences in the changes in NEI VFQ-25 TR subscale and composite scores in relation to educational status. Discussion: Significant improvements in BCVA, macular edema, and vision-related quality of life were found in DME patients who received IVR injections with a loading dose, as shown by the NEI VFQ-25 TR. Interestingly, a significant improvement in quality of life was observed even though the patients could see well with the fellow eye. In conclusion, the NEI VFQ-25 TR is a useful scale to evaluate the changes in visual function and psychosocial characteristics of DME patients after treatment.

scholarly journals Differential Impact of Unilateral and Bilateral Classifications of Diabetic Retinopathy and Diabetic Macular Edema on Vision-Related Quality of Life

2016 ◽  
Vol 57 (11) ◽  
pp. 4655 ◽  
Author(s):  
Ryan Eyn Kidd Man ◽  
Eva K. Fenwick ◽  
Charumathi Sabanayagam ◽  
Ling-Jun Li ◽  
Ching Siong Tey ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Differential Impact ◽  
Related Quality

scholarly journals Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
John R. Gonder ◽  
Valery M. Walker ◽  
Martin Barbeau ◽  
Nancy Zaour ◽  
Bryan H. Zachau ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Severe Loss ◽  
Telephone Interviews ◽  
Related Quality ◽  
Visual Acuity Loss ◽  
Composite Scores

Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients.Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-seeing eye was assessed at months 0 and 6. DME-related healthcare costs were determined over 6 months, and vision-related (National Eye Institute Visual Functioning Questionnaire) and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6.Results. Mean age of patients was 63.7 years: 52% were male and 72% had bilateral DME. At baseline, visual acuity was categorized as normal/mild loss for 63.4% of patients, moderate loss for 10.4%, and severe loss/nearly blind for 26.2%. Mean 6-month DME-related costs/patient were as follows: all patients (n=135), $2,092; normal/mild loss (n=88), $1,776; moderate loss (n=13), $1,845; and severe loss/nearly blind (n=34), $3,007. Composite scores for vision-related quality of life declined with increasing visual acuity loss; generic quality of life scores were highest for moderate loss and lowest for severe loss/nearly blind.Conclusions. DME-related costs in the Canadian healthcare system are substantial. Costs increased and vision-related quality of life declined with increasing visual acuity severity.

Changes in vision related quality of life in patients with diabetic macular edema: Ranibizumab or laser treatment?

2015 ◽  
Vol 29 (4) ◽  
pp. 540-543 ◽  
Author(s):  
Elif Betul Turkoglu ◽  
Erkan Celık ◽  
Nilgun Aksoy ◽  
Ozlem Bursalı ◽  
Turgay Ucak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Macular Edema ◽  
Laser Treatment ◽  
Diabetic Macular Edema ◽  
Related Quality
Sign in / Sign up

Export Citation Format

Share Document